Two decades ago, manufacturers launched patient support services to counter a distorted pharmaceutical supply chain - one designed for intermediaries, not patients, that shifts complexity and cost ...
Lynkuet is the first dual neurokinin receptor antagonist approved for moderate to severe VMS in menopause, offering a hormone-free treatment option. Phase III OASIS trials showed significant ...
In today’s Pharmaceutical Executive Daily, we cover the emergence of TrumpRx and its implications for direct-to-consumer drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback